Bernard Coulie, President & CEO of Pliant Therapeutics, discusses his career trajectory and experiences in the pharmaceutical industry, the challenges of developing microbiome-based drugs, and the acquisition of his co-founded company. He reflects on the importance of access to capital, building a strong team, and the differences between the biotech ecosystems in Europe and the US. Additionally, he talks about the challenges of resource allocation in their pipeline review process and their focus on idiopathic pulmonary fibrosis as their lead indication.
